Cargando…
Extraventricular Neurocytoma: Clinical Investigation of Heterogenous Prognosis
BACKGROUND: Extraventricular neurocytoma (EVN) is an extremely rare neuronal neoplasm that arises outside the ventricle. The clinical implication of the heterogenous prognosis of this rare tumor has not yet been clarified. Herein, we analyzed our institutional series of EVN. METHODS: A total of eigh...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Brain Tumor Society; The Korean Society for Neuro-Oncology; The Korean Society for Pediatric Neuro-Oncology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819464/ https://www.ncbi.nlm.nih.gov/pubmed/35118844 http://dx.doi.org/10.14791/btrt.2022.10.e30 |
_version_ | 1784646068222296064 |
---|---|
author | Byun, Joonho Kim, Moinay Song, Sang Woo Kim, Young-Hoon Hong, Chang Ki Kim, Jeong Hoon |
author_facet | Byun, Joonho Kim, Moinay Song, Sang Woo Kim, Young-Hoon Hong, Chang Ki Kim, Jeong Hoon |
author_sort | Byun, Joonho |
collection | PubMed |
description | BACKGROUND: Extraventricular neurocytoma (EVN) is an extremely rare neuronal neoplasm that arises outside the ventricle. The clinical implication of the heterogenous prognosis of this rare tumor has not yet been clarified. Herein, we analyzed our institutional series of EVN. METHODS: A total of eight consecutive cases were enrolled and investigated. The prognosis of EVN was analyzed and compared to that of central neurocytoma (CN). RESULTS: There were two male and six female patients, and the median age was 36.5 years. The median tumor size was 38 mm, and the most common location of the tumor was the frontal lobe (3, 37.5%), followed by the parietal and temporal lobes. In brain imaging, four (50%) tumors showed peritumoral edema and three (37.5%) tumors showed calcification. All patients underwent gross total resection, and two (25%) underwent adjuvant radiotherapy. The 5-year overall survival (OS) was 55.6%, and the 2-year progression-free survival (PFS) was 42.9%. The OS and PFS of EVN were poor compared to those of CN. Although EVN is a single disease entity, individual patients showed varying prognosis. One patient showed no recurrence during the 7-year follow-up period; however, another patient had a recurrence 4 months after surgery and died 2 years later. CONCLUSION: EVN may be a heterogenous disease entity. Additional cases with long-term followup are needed to develop optimal management protocols. |
format | Online Article Text |
id | pubmed-8819464 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Korean Brain Tumor Society; The Korean Society for Neuro-Oncology; The Korean Society for Pediatric Neuro-Oncology |
record_format | MEDLINE/PubMed |
spelling | pubmed-88194642022-02-15 Extraventricular Neurocytoma: Clinical Investigation of Heterogenous Prognosis Byun, Joonho Kim, Moinay Song, Sang Woo Kim, Young-Hoon Hong, Chang Ki Kim, Jeong Hoon Brain Tumor Res Treat Original Article BACKGROUND: Extraventricular neurocytoma (EVN) is an extremely rare neuronal neoplasm that arises outside the ventricle. The clinical implication of the heterogenous prognosis of this rare tumor has not yet been clarified. Herein, we analyzed our institutional series of EVN. METHODS: A total of eight consecutive cases were enrolled and investigated. The prognosis of EVN was analyzed and compared to that of central neurocytoma (CN). RESULTS: There were two male and six female patients, and the median age was 36.5 years. The median tumor size was 38 mm, and the most common location of the tumor was the frontal lobe (3, 37.5%), followed by the parietal and temporal lobes. In brain imaging, four (50%) tumors showed peritumoral edema and three (37.5%) tumors showed calcification. All patients underwent gross total resection, and two (25%) underwent adjuvant radiotherapy. The 5-year overall survival (OS) was 55.6%, and the 2-year progression-free survival (PFS) was 42.9%. The OS and PFS of EVN were poor compared to those of CN. Although EVN is a single disease entity, individual patients showed varying prognosis. One patient showed no recurrence during the 7-year follow-up period; however, another patient had a recurrence 4 months after surgery and died 2 years later. CONCLUSION: EVN may be a heterogenous disease entity. Additional cases with long-term followup are needed to develop optimal management protocols. The Korean Brain Tumor Society; The Korean Society for Neuro-Oncology; The Korean Society for Pediatric Neuro-Oncology 2022-01 2022-01-28 /pmc/articles/PMC8819464/ /pubmed/35118844 http://dx.doi.org/10.14791/btrt.2022.10.e30 Text en Copyright © 2022 The Korean Brain Tumor Society, The Korean Society for Neuro-Oncology, and The Korean Society for Pediatric Neuro-Oncology https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Byun, Joonho Kim, Moinay Song, Sang Woo Kim, Young-Hoon Hong, Chang Ki Kim, Jeong Hoon Extraventricular Neurocytoma: Clinical Investigation of Heterogenous Prognosis |
title | Extraventricular Neurocytoma: Clinical Investigation of Heterogenous Prognosis |
title_full | Extraventricular Neurocytoma: Clinical Investigation of Heterogenous Prognosis |
title_fullStr | Extraventricular Neurocytoma: Clinical Investigation of Heterogenous Prognosis |
title_full_unstemmed | Extraventricular Neurocytoma: Clinical Investigation of Heterogenous Prognosis |
title_short | Extraventricular Neurocytoma: Clinical Investigation of Heterogenous Prognosis |
title_sort | extraventricular neurocytoma: clinical investigation of heterogenous prognosis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819464/ https://www.ncbi.nlm.nih.gov/pubmed/35118844 http://dx.doi.org/10.14791/btrt.2022.10.e30 |
work_keys_str_mv | AT byunjoonho extraventricularneurocytomaclinicalinvestigationofheterogenousprognosis AT kimmoinay extraventricularneurocytomaclinicalinvestigationofheterogenousprognosis AT songsangwoo extraventricularneurocytomaclinicalinvestigationofheterogenousprognosis AT kimyounghoon extraventricularneurocytomaclinicalinvestigationofheterogenousprognosis AT hongchangki extraventricularneurocytomaclinicalinvestigationofheterogenousprognosis AT kimjeonghoon extraventricularneurocytomaclinicalinvestigationofheterogenousprognosis |